Welcome to OncoLink RxReview^TM

The goal of OncoLink RxReview^TM is to provide oncologists and other oncology healthcare professionals with the most recent data from phase II/III clinical studies of available anticancer agents. The rapid dissemination of clinical trial results is of key importance when designing appropriate treatment strategies for cancer patients, especially for those whose disease is resistant or refractory to first-line or standard therapies.

We hope that the information within will help you to:

1. Familiarize yourself with the efficacy and safety profiles of new agents
2. Discover new roles for established agents and
3. Optimize patient care and treatment outcomes

Important Information For the Healthcare Professional

Although every effort has been made to ensure that drug doses and other information are presented accurately throughout this web site, the ultimate responsibility for patient care rests with the prescribing physician and healthcare team. Neither the publishers nor the editors can be held responsible for errors or any other consequences arising from the use of information contained herein. Some references to the use of anticancer agents may be inconsistent with the approved labeling. Therefore, it is recommended that the reader consult the full prescribing information.

Important Information For the Patient

OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your healthcare provider.

Login